• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva Medical’s Fantom bioresorbable scaffold succeeds in two-year trial

May 25, 2018 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) touted sustained safety and efficacy results for its Fantom bioresorbable scaffold at this year’s EuroPCR meeting.

The company also revealed new information about its suite of Fantom Encore products, noting that the devices will have strut profiles of 95 microns, 105 microns and 115 microns.

Reva’s Fantom II trial included 240 patients and a primary endpoint consisting of cardiac death, myocardial infarction and target lesion revascularization. The company reported a 5% rate of major adverse cardiac events after two years, pointing out that it compares favorably with the 6-11% target lesion failure rates usually seen with drug-eluting stents or bioresorbable scaffolds.

The study’s investigators reported a 0.4% rate of scaffold thrombosis, as well as sustained vessel lumen patency without evidence of chronic scaffold recoil, Reva said.

“The 2-year results from the Fantom II trial are very promising for Fantom,” said Dr. Alexandre Abizaid, who presented the results at EuroPCR. “Fantom offers advantages relative to first-generation bioresorbable scaffolds such as a thinner strut profile and x-ray visibility. The data indicate that Fantom’s advantages are translating into positive outcomes for patients.”

Reva’s Fantom devices are made using a proprietary bioresorbable polymer called Tyrocore. Early bioresorbable scaffolds have suffered due to concerns about a heightened risk of myocardial infarction and scaffold thrombosis linked to the devices. But Reva has argued that first-gen scaffolds were limited, in part, due to their thick strut profiles.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Vascular, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS